Using a new, rapid and less expensive DNA sequencing strategy, scientists have discovered genetic alterations that account for most cases of Kabuki syndrome, a rare disorder that causes multiple birth defects and mental retardation. Instead of sequencing the entire human genome, the new approach sequences just the exome, the 1-2 percent of the human genome that contains protein-coding genes.
Related Post
- Gene Therapy Extends Mouse Lifespan - May 17th, 2012
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012
- Gene Therapy for Brain Disease - May 17th, 2012
- Gene therapy dramatically extends mouse lifespan - May 17th, 2012
- Gene therapy extends mouse lifespan by 24 pc - May 17th, 2012
- Molecular subtypes and genetic alterations may determine response to lung cancer therapy - May 13th, 2012
- Genetic testing for drug intolerance - May 13th, 2012
- Huntington's disease: genetic disorder of cognitive and motor decline - May 13th, 2012
- Diagnosing a Rare, Genetic Disease - May 13th, 2012
- Genetic Technologies Executes Settlement and License Agreement With GeneSeek Inc. - May 13th, 2012
- Repost: Depressed mice, gene therapy, and p11 - May 13th, 2012
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 13th, 2012
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012
- Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma - May 13th, 2012
- Zinc Finger Protein Designed to Target 2-Long Terminal Repeat Junctions Interferes with Human Immunodeficiency Virus Integration - May 13th, 2012
- A Shield Against Chemotherapy - May 13th, 2012
- Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome - May 13th, 2012
- A paradigm shift in the delivery of services for diagnosis of inherited retinal disease - May 13th, 2012
- Human Gene Therapy highlights new advances in human retinal disease - May 10th, 2012
- Penn researchers report a gene-therapy success - May 10th, 2012
- MicroRNA silencing improves the tumor specificity of adenoviral transgene expression - May 6th, 2012
- Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC - May 6th, 2012
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning - May 6th, 2012
- MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy - May 6th, 2012
- Critical Variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency - May 6th, 2012
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 6th, 2012
- HIV Gene Therapy Safe Over Time (CME/CE) - May 6th, 2012
- Nanovector delivery of siRNA for cancer therapy - May 6th, 2012
- Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model - May 6th, 2012
- Interferon-? lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-? gene transfer to human tumor cells - May 6th, 2012
- Gene Hunt Is On for Mental Disabilities in Children - May 6th, 2012
- Gene therapy for HIV safe, but effectiveness still unclear - May 5th, 2012
- Gene Therapy Convention I-SMART on May 2nd 2012, 4 PM to 7 PM, at Bangalore Under the Aegis of DRDO, DST, Dr.Agarwal ... - April 30th, 2012
- Global Gene Therapy Industry - April 29th, 2012
- Research and Markets: Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders - April 29th, 2012
- Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice - April 29th, 2012
- Epirubicin potentiates recombinant adeno?associated virus type 2/5–mediated TRAIL expression in fibroblast?like synoviocytes and augments the antiarthritic effects of rAAV2/5?TRAIL - April 29th, 2012
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results - April 29th, 2012
- Prospects for gene transfer for clinical heart failure - April 29th, 2012
- Gene therapy for ventricular tachyarrhythmias - April 29th, 2012